Authors,Author(s) ID,Title,Year,Source tittle,Cited by,DOI,Country,Document Type,City,Access Type,aggregationType,EID
Juengel E.,,HDAC-inhibition counteracts everolimus resistance in renal cell carcinoma in vitro by diminishing cdk2 and cyclin A,2014,Molecular Cancer,34,10.1186/1476-4598-13-152,Germany,Article,Frankfurt am Main,1,Journal,2-s2.0-84903454960
Hsieh Y.J.,,P21-driven multifusion gene system for evaluating the efficacy of histone deacetylase inhibitors by in vivo molecular imaging and for transcription targeting therapy of cancer mediated by histone deacetylase inhibitor,2014,Journal of Nuclear Medicine,8,10.2967/jnumed.113.126573,Taiwan,Article,Kaohsiung,1,Journal,2-s2.0-84901315813
Fortunati N.,,The pan-histone deacetylase inhibitor LBH589 (panobinostat) alters the invasive breast cancer cell phenotype,2014,International Journal of Oncology,16,10.3892/ijo.2013.2218,Italy,Article,Torino,1,Journal,2-s2.0-84896725560
Zhao Y.,,"Anticancer activity of SAHA, a potent histone deacetylase inhibitor, in NCI-H460 human large-cell lung carcinoma cells in vitro and in vivo",2014,International Journal of Oncology,17,10.3892/ijo.2013.2193,China,Article,Wuhan,1,Journal,2-s2.0-84894411815
West A.,,New and emerging HDAC inhibitors for cancer treatment,2014,Journal of Clinical Investigation,786,10.1172/JCI69738,Australia,Review,Melbourne,0,Journal,2-s2.0-84892942381
Yan S.F.,,HDAC inhibitor sodium butyrate augments the MEF2C enhancement of Nampt expression under hypoxia,2014,Current Pharmaceutical Design,5,10.2174/13816128113199990544,China,Article,Beijing,0,Journal,2-s2.0-84903705180
Ren J.,,HDAC as a therapeutic target for treatment of endometrial cancers,2014,Current Pharmaceutical Design,13,10.2174/13816128113199990528,China,Review,Xi'an,0,Journal,2-s2.0-84903701799
Götze S.,,Histone deacetylase inhibitors induce attenuation of Wnt signaling and TCF7L2 depletion in colorectal carcinoma cells,2014,International Journal of Oncology,14,10.3892/ijo.2014.2550,Germany,Article,Dortmund,1,Journal,2-s2.0-84907466558
Wang L.,,"A novel class I HDAC inhibitor, MPT0G030, induces cell apoptosis and differentiation in human colorectal cancer cells via HDAC1/PKCδ and E-cadherin",2014,Oncotarget,24,10.18632/oncotarget.2155,Taiwan,Article,Taipei,1,Journal,2-s2.0-84906234182
Li X.,,Progress of HDAC inhibitor panobinostat in the treatment of cancer,2014,Current Drug Targets,29,10.2174/1389450115666140306152642,China,Review,Jinan,0,Journal,2-s2.0-84899844914
Valente S.,,Small-molecule inhibitors of histone deacetylase for the treatment of cancer and non-cancer diseases: A patent review (2011-2013),2014,Expert Opinion on Therapeutic Patents,31,10.1517/13543776.2014.877446,Italy,Review,Rome,0,Journal,2-s2.0-84896470334
Hrabeta J.,,Histone deacetylase inhibitors in cancer therapy. A review,2014,Biomedical Papers,37,10.5507/bp.2013.085,Czech Republic,Review,Prague Praha,1,Journal,2-s2.0-84903612130
Kroesen M.,,HDAC inhibitors and immunotherapy; A double edged sword?,2014,Oncotarget,89,10.18632/oncotarget.2289,Netherlands,Article,Nijmegen,1,Journal,2-s2.0-84907068045
Ooki A.,,"DNA damage-inducible gene, Reprimo functions as a tumor suppressor and is suppressed by promoter methylation in gastric cancer",2013,Molecular Cancer Research,26,10.1158/1541-7786.MCR-13-0091,Japan,Article,Tokyo,1,Journal,2-s2.0-84888244590
Song X.,,LBH589 Inhibits proliferation and metastasis of hepatocellular carcinoma via inhibition of gankyrin/stat3/akt pathway,2013,Molecular Cancer,46,10.1186/1476-4598-12-114,China,Article,Harbin,1,Journal,2-s2.0-84884918389
Jeon Y.,,"The HDAC inhibitor, panobinostat, induces apoptosis by suppressing the expresssion of specificity protein 1 in oral squamous cell carcinoma",2013,International Journal of Molecular Medicine,16,10.3892/ijmm.2013.1451,South Korea,Article,Jeonju,1,Journal,2-s2.0-84883340020
Tarhini A.A.,,Phase I trial of carboplatin and etoposide in combination with panobinostat in patients with lung cancer,2013,Anticancer Research,19,,United States;United States,Article,Pittsburgh;Pittsburgh,0,Journal,2-s2.0-84891350230
Brilli L.,,HDAC inhibitors in kidney development and disease,2013,Pediatric Nephrology,34,10.1007/s00467-012-2320-8,United States,Review,Pittsburgh,1,Journal,2-s2.0-84883303698
Wang G.,,"Panobinostat Synergistically Enhances the Cytotoxic Effects of Cisplatin, Doxorubicin or Etoposide on High-Risk Neuroblastoma Cells",2013,PLoS ONE,22,10.1371/journal.pone.0076662,United States;China,Article,Detroit;Changchun,1,Journal,2-s2.0-84884778458
Chuang M.,,The HDAC Inhibitor LBH589 Induces ERK-Dependent Prometaphase Arrest in Prostate Cancer via HDAC6 Inactivation and Down-Regulation,2013,PLoS ONE,26,10.1371/journal.pone.0073401,Taiwan,Article,Taipei,1,Journal,2-s2.0-84883423841
Xiao W.,,Combination Therapy with the Histone Deacetylase Inhibitor LBH589 and Radiation Is an Effective Regimen for Prostate Cancer Cells,2013,PLoS ONE,19,10.1371/journal.pone.0074253,China;Australia;China;Australia,Article,Guangzhou;Sydney;Guangzhou;Sydney,1,Journal,2-s2.0-84883137069
Mithraprabhu S.,,Histone deacetylase (HDAC) inhibitors as single agents induce multiple myeloma cell death principally through the inhibition of class I HDAC,2013,British Journal of Haematology,27,10.1111/bjh.12388,Australia,Letter,Melbourne,1,Journal,2-s2.0-84880696667
De Marinis F.,,A phase II study of the histone deacetylase inhibitor panobinostat (LBH589) in pretreated patients with small-cell lung cancer,2013,Journal of Thoracic Oncology,32,10.1097/JTO.0b013e318293d88c,Italy,Article,Rome,1,Journal,2-s2.0-84880886469
Scuto A.,,SIRT1 activation enhances HDAC inhibition-mediated upregulation of GADD45G by repressing the binding of NF-κB/STAT3 complex to its promoter in malignant lymphoid cells,2013,Cell Death and Disease,29,10.1038/cddis.2013.159,United States,Article,Duarte,1,Journal,2-s2.0-84879369058
Ghobrial I.M.,,Results of a phase 2 trial of the single-agent histone deacetylase inhibitor panobinostat in patients with relapsed/refractory Waldenström macroglobulinemia,2013,Blood,46,10.1182/blood-2012-06-439307,United States,Article,Boston,1,Journal,2-s2.0-84874401753
Russo D.,,Targeting histone deacetylase in thyroid cancer,2013,Expert Opinion on Therapeutic Targets,19,10.1517/14728222.2013.740013,Italy,Review,Catanzaro,0,Journal,2-s2.0-84872250456
Bellucci L.,,Activation of p21 by HDAC Inhibitors Requires Acetylation of H2A.Z,2013,PLoS ONE,26,10.1371/journal.pone.0054102,France;France,Article,Toulouse;Paris,1,Journal,2-s2.0-84872530682
Xu M.,,Histone deacetylase inhibitors induce human renal cell carcinoma cell apoptosis through p-JNK activation.,2013,Nan fang yi ke da xue xue bao = Journal of Southern Medical University,5,,China,Article,Guangzhou,0,Journal,2-s2.0-84900368376
Woods D.M.,,The antimelanoma activity of the histone deacetylase inhibitor panobinostat (LBH589) is mediated by direct tumor cytotoxicity and increased tumor immunogenicity,2013,Melanoma Research,49,10.1097/CMR.0b013e328364c0ed,United States;United States,Article,Tampa;Tampa,0,Journal,2-s2.0-84887994817
Tao Y.F.,,Survivin selective inhibitor YM155 induce apoptosis in SK-NEP-1 Wilms tumor cells,2012,BMC Cancer,39,10.1186/1471-2407-12-619,China,Article,Suzhou,1,Journal,2-s2.0-84871527859
Yu G.,,LncRNAs expression signatures of renal clear cell carcinoma revealed by microarray,2012,PLoS ONE,89,10.1371/journal.pone.0042377,China,Article,Wuhan,1,Journal,2-s2.0-84864653060
Xu M.,,"Reprimo (RPRM) is a novel tumor suppressor in pituitary tumors and regulates survival, proliferation, and tumorigenicity",2012,Endocrinology,27,10.1210/en.2011-2021,United States;United States,Article,;Denver,1,Journal,2-s2.0-84862728850
Davenport K.,,"Pediatric Malignancies. Neuroblastoma, Wilm's Tumor, Hepatoblastoma, Rhabdomyosarcoma, and Sacroccygeal Teratoma.",2012,Surgical Clinics of North America,27,10.1016/j.suc.2012.03.004,United States,Review,"Washington, D.C.",0,Journal,2-s2.0-84861009918
Lemaire M.,,The HDAC inhibitor LBH589 enhances the antimyeloma effects of the IGF-1RTK inhibitor picropodophyllin,2012,Clinical Cancer Research,13,10.1158/1078-0432.CCR-11-1764,Belgium,Article,Brussels,1,Journal,2-s2.0-84859822013
Bahari-Javan S.,,HDAC1 regulates fear extinction in mice,2012,Journal of Neuroscience,128,10.1523/JNEUROSCI.0079-12.2012,Germany;Germany,Article,Gottingen;Gottingen,1,Journal,2-s2.0-84859540297
Wegert J.,,Retinoic acid pathway activity in wilms tumors and characterization of biological responses in vitro,2011,Molecular Cancer,18,10.1186/1476-4598-10-136,Germany,Article,Wurzburg,1,Journal,2-s2.0-80455126026
Ma Y.,,Low-dose LBH589 increases the sensitivity of cisplatin to cisplatin-resistant ovarian cancer cells,2011,Taiwanese Journal of Obstetrics and Gynecology,9,10.1016/j.tjog.2011.01.022,Taiwan;Taiwan,Article,Taoyuan;Taipei,1,Journal,2-s2.0-79960635636
Chou C.,,HDAC inhibition decreases the expression of EGFR in colorectal cancer cells,2011,PLoS ONE,74,10.1371/journal.pone.0018087,Taiwan,Article,Taipei,1,Journal,2-s2.0-79953044882
Oehme I.,,Histone deacetylase 8 in neuroblastoma tumorigenesis,2009,Clinical Cancer Research,233,10.1158/1078-0432.CCR-08-0684,Germany,Article,Heidelberg,1,Journal,2-s2.0-58849104486
Bernal C.,,Reprimo as a potential biomarker for early detection in gastric cancer,2008,Clinical Cancer Research,89,10.1158/1078-0432.CCR-07-4522,Chile,Article,Santiago,1,Journal,2-s2.0-58149147357
Scuto A.,,"The novel histone deacetylase inhibitor, LBH589, induces expression of DNA damage response genes and apoptosis in Ph <sup>-</sup> acute lymphoblastic leukemia cells",2008,Blood,98,10.1182/blood-2007-10-117762,United States,Article,Duarte,0,Journal,2-s2.0-46749139575
Crump M.,,Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid) in relapsed diffuse large-B-cell lymphoma,2008,Annals of Oncology,139,10.1093/annonc/mdn031,Canada,Article,Toronto,1,Journal,2-s2.0-43049092663
Beasley W.D.,,Reprimo 824 G&gt;C and p53R2 4696 C&gt;G single nucleotide polymorphisms and colorectal cancer: A case-control disease association study,2008,International Journal of Colorectal Disease,10,10.1007/s00384-007-0435-3,United Kingdom;United Kingdom,Article,Swansea;Swansea,0,Journal,2-s2.0-42649102634
Weichert W.,,Class I histone deacetylase expression has independent prognostic impact in human colorectal cancer: Specific role of class I histone deacetylases in vitro and in vivo,2008,Clinical Cancer Research,261,10.1158/1078-0432.CCR-07-0990,Germany,Article,Berlin,1,Journal,2-s2.0-41549159879
Smith M.A.,,SK-NEP-1 and Rh1 are Ewing family tumor lines,2008,Pediatric Blood and Cancer,49,10.1002/pbc.21099,United States,Article,Bethesda,0,Journal,2-s2.0-38549136783
Darzynkiewicz Z.,,Analysis of apoptosis by cytometry using TUNEL assay,2008,Methods,132,10.1016/j.ymeth.2007.11.008,United States,Article,Valhalla,0,Journal,2-s2.0-39749163470
Richardson P.,,"Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma",2008,Leukemia and Lymphoma,164,10.1080/10428190701817258,United States,Article,Boston,0,Journal,2-s2.0-39749103428
Nakagawa M.,,Expression profile of class I histone deacetylases in human cancer tissues,2007,Oncology Reports,241,10.3892/or.18.4.769,Japan,Article,Fukuoka,1,Journal,2-s2.0-38449100788
Bolden J.,,Anticancer activities of histone deacetylase inhibitors,2006,Nature Reviews Drug Discovery,2283,10.1038/nrd2133,Australia;Australia,Review,Melbourne;Parkville,0,Journal,2-s2.0-33748451151
Graham C.,,"Evaluation of the antitumor efficacy, pharmacokinetics, and pharmacodynamics of the histone deacetylase inhibitor depsipeptide in childhood cancer models in vivo",2006,Clinical Cancer Research,76,10.1158/1078-0432.CCR-05-1225,United States,Article,"Memphis TN,",1,Journal,2-s2.0-31544467339
Song J.,,Increased expression of histone deacetylase 2 is found in human gastric cancer,2005,APMIS,234,10.1111/j.1600-0463.2005.apm_04.x,South Korea,Article,Youngdeungpo,0,Journal,2-s2.0-21044447215
Zhu P.,,Induction of HDAC2 expression upon loss of APC in colorectal tumorigenesis,2004,Cancer Cell,396,10.1016/S1535-6108(04)00114-X,United States;Germany,Article,San Diego;Eggenstein-Leopoldshafen,1,Journal,2-s2.0-2342603414
Yasui W.,,Histone acetylation and gastrointestinal carcinogenesis,2003,Annals of the New York Academy of Sciences,125,10.1111/j.1749-6632.2003.tb05977.x,Japan,Conference Paper,Higashihiroshima,0,Book Series,2-s2.0-0037354555
Ohki R.,,"Reprimo, a new candidate mediator of the p53-mediated cell cycle arrest at the G<inf>2</inf> phase",2000,Journal of Biological Chemistry,133,10.1074/jbc.C000235200,Japan,Article,Tokyo,1,Journal,2-s2.0-0034725694
